Kava capsules tested as a mobility aid for seniors over 70

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 70 years * 8 ≤ Insomnia severity index (ISI) ≤21 * 4m walking speed \<1 m/sec and \>0.44 m/sec * Mild to moderate physical impairment (Short Physical Performance Battery score \< 10) * Sedentary lifestyle (\< 150 min per week of moderate intensity physical activity) verified by CHAMPS questionnaire * Willingness and ability to give informed consent * Willingness to be randomized to the intervention groups * Availability for participation through duration of study Exclusion Criteria (General) * Failure to provide informed consent * History or clinical manifestation of diabetes, cholelithiasis, liver or renal disease, cancer, or progressive, degenerative neurologic disease (e.g., Parkinson's Disease, multiple sclerosis, ALS) * Abnormal laboratory markers (e.g., renal or liver abnormalities, elevated potassium levels, or hemoglobin and hematocrit below the lower limit of normal) * Residence in a Skilled Nursing Facility (SNF); residence in an Assisted Living Facility (ALF) or independent housing is allowed * Self-reported inability to walk one block * Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental Status Exam score \< 24 * Severe rheumatologic or orthopedic diseases (e.g., awaiting joint replacement, active inflammatory disease) * Terminal illness with life expectancy less than 12 months, as determined by a physician * Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina * Severe pulmonary disease, pneumonitis or interstitial lung disease * Other significant co-morbid disease (e.g. renal failure on hemodialysis) or severe psychiatric disorder (e.g. bipolar, schizophrenia) * Current use of antidepressant medications, antipsychotic agents, monoamine oxidase inhibitors, anticholinesterase inhibitors (i.e., Aricept) * Refuses to reduce alcohol use to 3 or fewer alcoholic drinks per week during the study * Planning to permanently leave the area in the next year * Blood pressure readings \>180/100 at screening * Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment. Exclusion Criteria (AB-free kava-related) * Regular use of any medications that contain acetaminophen * Current use of any forms of kava and not willing to stop for a 2-week washout period - dietary supplements or beverages * Current use of antidepressant medications and antipsychotic agents (including monoamine oxidase inhibitors), or anticholinesterase inhibitors (i.e., Aricept) * Diagnosed with liver dysfunction or with previous liver diseases during the past five years * Levels of ALT, AST, ALP or total bilirubin over 3xlimit of normal (ULN) range at prescreen Temporary Exclusion Criteria * Acute infection (urinary, respiratory, other) or hospitalization within 1 month * Myocardial infarction, CABG, or valve replacement within past 6 months * Pulmonary embolism or deep venous thrombosis within past 6 months * Stroke, hip fracture, hip or knee replacement, or spinal surgery within past 4 months * Receiving physical therapy for gait, balance, or other lower extremity training